Latest News & Insight: October 27, 2014

Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.